Dimensional Fund Advisors LP lessened its stake in shares of Nuvectra Corp (NASDAQ:NVTR) by 0.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 738,043 shares of the company’s stock after selling 5,150 shares during the quarter. Dimensional Fund Advisors LP owned about 5.22% of Nuvectra worth $9,609,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Rockefeller Capital Management L.P. purchased a new stake in shares of Nuvectra during the first quarter worth approximately $5,593,000. Wells Fargo & Company MN raised its stake in shares of Nuvectra by 14.6% during the fourth quarter. Wells Fargo & Company MN now owns 127,665 shares of the company’s stock worth $991,000 after purchasing an additional 16,244 shares during the last quarter. Hodges Capital Management Inc. raised its stake in shares of Nuvectra by 22.9% during the first quarter. Hodges Capital Management Inc. now owns 268,013 shares of the company’s stock worth $3,490,000 after purchasing an additional 49,999 shares during the last quarter. Granite Investment Partners LLC purchased a new stake in shares of Nuvectra during the first quarter worth approximately $471,000. Finally, JPMorgan Chase & Co. raised its stake in shares of Nuvectra by 1,053.5% during the first quarter. JPMorgan Chase & Co. now owns 19,309 shares of the company’s stock worth $251,000 after purchasing an additional 17,635 shares during the last quarter. Institutional investors and hedge funds own 69.41% of the company’s stock.

Several equities research analysts have recently commented on the company. SunTrust Banks upped their price target on Nuvectra to $27.00 and gave the stock a “buy” rating in a research note on Thursday, June 21st. Zacks Investment Research raised Nuvectra from a “sell” rating to a “hold” rating in a report on Friday, June 15th. ValuEngine raised Nuvectra from a “hold” rating to a “buy” rating in a report on Saturday, June 2nd. Finally, BidaskClub lowered Nuvectra from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 3rd. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $19.50.

Shares of Nuvectra opened at $16.27 on Friday, Marketbeat Ratings reports. Nuvectra Corp has a 1-year low of $7.60 and a 1-year high of $23.66. The firm has a market cap of $229.85 million, a P/E ratio of -3.61 and a beta of -1.98. The company has a current ratio of 5.51, a quick ratio of 5.15 and a debt-to-equity ratio of 0.61.

Nuvectra (NASDAQ:NVTR) last announced its quarterly earnings data on Wednesday, May 2nd. The company reported ($0.84) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.89) by $0.05. Nuvectra had a negative return on equity of 72.39% and a negative net margin of 112.42%. The firm had revenue of $10.57 million for the quarter, compared to analyst estimates of $9.71 million. equities analysts predict that Nuvectra Corp will post -3.7 EPS for the current fiscal year.

Nuvectra Profile

Nuvectra Corporation, a neuromodulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. It operates through two segments, Nuvectra and NeuroNexus. The company offers Algovita spinal cord stimulation system that is used for the treatment of chronic pain of the trunk and limbs.

Recommended Story: Understanding Analyst Recommendations

Institutional Ownership by Quarter for Nuvectra (NASDAQ:NVTR)

Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.